The purpose of the study is to compare the incidence of contrast induced nephrotoxicity
following the administration of Isovue or Visipaque in patients with mild to moderate renal
impairment who undergo a clinically indicated IV contrast-enhanced (multidetector computed
tomography) MDCT of the liver or MDCT angiography of the lower extremities. Serum Creatinine
(SCr) will be measured before and up to 48-72 hours post dose.